Last reviewed · How we verify
Autologous, DNP-Modified Melanoma Vaccine
At a glance
| Generic name | Autologous, DNP-Modified Melanoma Vaccine |
|---|---|
| Also known as | MVax |
| Sponsor | AVAX Technologies |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma (PHASE2)
- M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma (PHASE3)
- Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: